Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis
Dirk Steffen Koschel, Martin Kolditz, Gert Hoeffken, Michael Halank
Med Sci Monit 2010; 16(5): CS55-57
Available online: 2010-04-28
There are only a few reports of pulmonary hypertension (PH) in hypersensitivity pneumonitis (HP) and an approved vasomodulatory therapy for PH does not exist at all for interstitial lung disease (ILD), particularly for HP.
Material and Method: The case of a 53-year-old woman with chronic HP and severe life-threatening PH treated with a combined specific vasomodulatory therapy is reported. Sustained clinical and hemodynamic improvement was achieved.
Conclusions: Further investigation of PH in HP and specific vasomodulatory therapy is necessary.
Keywords: Sulfones - therapeutic use, Pyridazines - therapeutic use, Purines - therapeutic use, Piperazines - therapeutic use, Phenylpropionates - therapeutic use, Middle Aged, Iloprost - therapeutic use, Hypertension, Pulmonary - drug therapy, Female, Humans, Drug Therapy, Combination, Chronic Disease, Alveolitis, Extrinsic Allergic - complications, Vasodilator Agents - therapeutic use